mRNA |
Erlotinib |
gCSI |
pan-cancer |
AAC |
0.11 |
0.06 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.069 |
0.06 |
mRNA |
AT7867 |
CTRPv2 |
pan-cancer |
AAC |
-0.067 |
0.06 |
mRNA |
MP470 |
GDSC1000 |
pan-cancer |
AAC |
0.062 |
0.06 |
mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.067 |
0.06 |
mRNA |
Sorafenib |
GDSC1000 |
pan-cancer |
AAC |
0.1 |
0.06 |
mRNA |
Doxorubicin |
GDSC1000 |
pan-cancer |
AAC |
-0.064 |
0.07 |
mRNA |
Parthenolide |
CTRPv2 |
pan-cancer |
AAC |
0.071 |
0.07 |
mRNA |
BMS-708163 |
GDSC1000 |
pan-cancer |
AAC |
-0.059 |
0.07 |
mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.065 |
0.07 |